FDA approves landmark pancreatic cancer drug that's shown to improve survival
After publishing: 3 headlines quietly rewritten3 changes
- nbcdfw.comseen 29 Aug, 03:29headline rewritten
FDA approves landmark pancreatic cancer drugFDA approves landmark pancreatic cancer drug that's shown to improve survival - sandiegouniontribune.comseen 29 Aug, 03:29headline rewritten
FDA approves landmark pancreatic cancer drug shown to improve survivalFDA approves landmark pancreatic cancer drug that’s shown to improve survival - yahoo.comseen 29 Aug, 03:38headline rewritten
Revolution Medicines gets FDA nod for targeted pancreatic cancer drugRevolution’s pancreatic cancer drug wins speedy FDA approval
The headline, as it mutated - 6 wordings
- 26 Aug, 15:58FDA approves landmark pancreatic cancer drug that's shown to improve survival7 outlets
- 26 Aug, 16:16'A critical new option': FDA approves pill for advanced pancreatic cancer8 outlets
- 26 Aug, 17:19FDA Approves First Targeted Pill For Advanced Pancreatic Cancer1 outlet
- 26 Aug, 18:15FDA approves breakthrough drug to treat advanced pancreatic cancer2 outlets
- 26 Aug, 18:38Revolution’s pancreatic cancer drug wins speedy FDA approval2 outlets
- 27 Aug, 08:56New Pill Doubles Survival Rate For Pancreatic Cancer Patients1 outlet
- and 31 one-off wordings
After the peak, new reports halved every 16 hours so far - this story is still being covered, so the figure moves as reports arrive.
What it is about
Who published it, and when
37 reports left out of the cascade - too little in common with the story to place
How it spread - 64 original reports, 13 reprints
Wed, 26 August 2026
45 reports- clickondetroit.com15:58
U.S. health officials have approved a groundbreaking pancreatic cancer drug that offers a new approach to treating the deadly form of cancer.
5 reprints
- news4jax.com26 Aug, 15:58their copy
- sandiegouniontribune.com26 Aug, 16:05their copy
- nbcdfw.com26 Aug, 16:32their copy
- NPR News27 Aug, 06:54their copy
- wclk.com27 Aug, 06:54their copy
- scientificamerican.com16:00first to report
Pancreatic cancer is considered one of the hardest to treat and most serious forms of cancer
- krcrtv.com16:16
U.S. health regulators approved a once-daily pill for adults with advanced pancreatic cancer, offering a new option for patients, according to the FDA.
7 reprints
- nebraska.tv26 Aug, 16:16their copy
- ktul.com26 Aug, 16:16their copy
- foxsanantonio.com26 Aug, 16:16their copy
- abc6onyourside.com26 Aug, 16:16their copy
- cbs4local.com26 Aug, 16:16their copy
- fox23.com26 Aug, 16:16their copy
- wsbt.com26 Aug, 16:16their copy
- The Guardian World16:48
FDA officials approve first-of-a-kind pill called daraxonrasib to fight one of the deadliest types of cancer The US Food and Drug Administration (FDA) approved a groundbreaking new drug for the most common form of pancreatic cancer, offering US patients a more effective treatment against one of the deadliest types of the disease. FDA officials gave expedited approval to the first-of-a-kind pill, called daraxonrasib, that blocks a mutated protein which fuels tumor growth in more than 90% of...
- iheart.com17:19
The breakthrough drug, from Revolution Medicines, could signal a new era in cancer treatment.
- iheart.com17:19
The breakthrough drug, from Revolution Medicines, could signal a new era in cancer treatment.
- iheart.com17:19
The breakthrough drug, from Revolution Medicines, could signal a new era in cancer treatment.
- iheart.com17:19
The breakthrough drug, from Revolution Medicines, could signal a new era in cancer treatment.
- iheart.com17:19
The breakthrough drug, from Revolution Medicines, could signal a new era in cancer treatment.
- iheart.com17:19
The breakthrough drug, from Revolution Medicines, could signal a new era in cancer treatment.
- iheart.com17:19
The breakthrough drug, from Revolution Medicines, could signal a new era in cancer treatment.
- iheart.com17:19
The breakthrough drug, from Revolution Medicines, could signal a new era in cancer treatment.
- iheart.com17:19
The breakthrough drug, from Revolution Medicines, could signal a new era in cancer treatment.
- iheart.com17:19
The breakthrough drug, from Revolution Medicines, could signal a new era in cancer treatment.
- iheart.com17:19
The breakthrough drug, from Revolution Medicines, could signal a new era in cancer treatment.
- iheart.com17:19
The breakthrough drug, from Revolution Medicines, could signal a new era in cancer treatment.
- iheart.com17:19
The breakthrough drug, from Revolution Medicines, could signal a new era in cancer treatment.
- iheart.com17:19
The breakthrough drug, from Revolution Medicines, could signal a new era in cancer treatment.
- iheart.com17:19
The breakthrough drug, from Revolution Medicines, could signal a new era in cancer treatment.
- iheart.com17:19
The breakthrough drug, from Revolution Medicines, could signal a new era in cancer treatment.
- iheart.com17:19
The breakthrough drug, from Revolution Medicines, could signal a new era in cancer treatment.
- iheart.com17:19
The breakthrough drug, from Revolution Medicines, could signal a new era in cancer treatment.
- iheart.com17:19
The breakthrough drug, from Revolution Medicines, could signal a new era in cancer treatment.
- iheart.com17:19
The breakthrough drug, from Revolution Medicines, could signal a new era in cancer treatment.
- iheart.com17:19
The breakthrough drug, from Revolution Medicines, could signal a new era in cancer treatment.
- iheart.com17:19
The breakthrough drug, from Revolution Medicines, could signal a new era in cancer treatment.
- ibtimes.co.uk17:28
The FDA has approved Rasonque, a new cancer pill, which nearly doubles survival rates in advanced pancreatic cancer patients, marking a significant advancement in treatment options.
- theepochtimes.com17:36
The drug helps extend the life of people with pancreatic cancer, according to a clinical trial.
- The Hill17:50
The Food and Drug Administration (FDA) on Wednesday approved a treatment for advanced pancreatic cancer, offering new life-extending care for patients with one of the most aggressive forms of cancer. The once-daily pill, called daraxonrasib and manufactured by Revolution Medicines, will be sold under the brand name Rasonque. It was approved for patients who already tried...
- Google News - Top Stories18:03
F.D.A. Approves the Drug Daraxonrasib That’s Poised to Transform Pancreatic Cancer The New York Times A Breakthrough Pancreatic Cancer Drug Marks a New Era for Treatment Bloomberg A major RAS drug milestone could spur interest in rival assets Axios FDA gives expedited approval to new groundbreaking pancreatic cancer drug The Guardian FDA Approves Drug for Pancreatic Cancer in Milestone for Treatment of Deadly Disease WSJ
- Le Figaro (France)18:08
Le traitement, nommé Rasonque et développé par la start-up américaine Revolution Medicines, a doublé la durée de survie de patients, selon son essai clinique.
- freerepublic.com18:15
- hitsfm.net18:15
FDA sign at its headquarters in Washington, D.C. (Getty Images stock photo/JHVEPhoto)(WASHINGTON) -- The Food and Drug Administration (FDA) approved on Wednesday a drug that could extend the survival of those with metastatic pancreatic cancer.The drug, called daraxonrasib, will be sold under the brand name Rasonque from Revolution Medicines. The daily pill targets multiple forms of a protein called RAS, which is a main driver of tumor growth.A late-stage clinical trial with 500 patients showed...
1 reprint
- ksyl.com26 Aug, 18:30their copy
- Google News - Top Stories18:21
FDA Approves Drug for Pancreatic Cancer in Milestone for Treatment of Deadly Disease WSJ F.D.A. Approves the Drug Daraxonrasib That’s Poised to Transform Pancreatic Cancer The New York Times FDA Okays RAS Inhibitor Daraxonrasib for Pancreatic Cancer Medscape A major RAS drug milestone could spur interest in rival assets Axios FDA approves landmark pancreatic cancer drug that’s shown to improve survival WPRI.com
- ksl.com18:30
The U.S. Food and Drug Administration on Wednesday approved Revolution Medicines' targeted drug for adults with metastatic pancreatic cancer who have received prior treatment or cannot receive combination chemotherapy.
- Il Fatto Quotidiano (Italy)18:34
Una compressa una volta al giorno e una nuova possibilità terapeutica per una delle forme di tumore più aggressive e difficili da trattare. Negli Stati Uniti la Food and Drug Administration (Fda) ha approvato daraxonrasib (Rasonque), terapia mirata “first in class” destinata agli adulti con adenocarcinoma pancreatico metastatico già sottoposti ad almeno una terapia sistemica […] L'articolo Cancro al pancreas metastatico, negli Usa via libera alla nuova terapia mirata in compresse proviene da Il...
- yahoo.com18:38edited after publishing
previously
Revolution Medicines gets FDA nod for targeted pancreatic cancer drugThe U.S. FDA has approved Revolution Medicines’ groundbreaking pancreatic cancer drug after it was shown to double the survival rate of patients with advanced disease in a large trial, offering new h...
- Google News - Top Stories19:16
Revolution's lifesaving pancreatic cancer drug wins speedy FDA approval Reuters F.D.A. Approves the Drug Daraxonrasib That’s Poised to Transform Pancreatic Cancer The New York Times FDA approves life-extending pancreatic cancer drug Rasonque USA Today A major RAS drug milestone could spur interest in rival assets Axios FDA Approves Drug for Pancreatic Cancer in Milestone for Treatment of Deadly Disease WSJ
- Le Monde English19:22
The US Food and Drug Administration announced its approval for a drug that could double the survival time of some patients for a type of cancer that has, historically, been difficult to treat.
- ktvz.com19:56
CENTRAL OREGON (KTVZ) -- The Food and Drug Administration approved daraxonrasib Aug. 26, offering a new treatment option for patients with stage 4 metastatic pancreatic cancer. Early research shows the medication doubles average life expectancy for patients with advanced stages of the disease from six to 13 months. Seven patients at St. Charles Cancer Institute
- wxyz.com20:17
The FDA has approved a new targeted drug for advanced pancreatic cancer. In a clinical trial, it helped patients live twice as long compared to those treated with standard chemotherapy.
- Google News - Top Stories21:53
FDA approves landmark pancreatic cancer drug that’s shown to improve survival AP News F.D.A. Approves Drug Poised to Transform Care for Pancreatic Cancer The New York Times FDA approves once-daily pill for deadly cancer after patients' survival rates nearly double Fox News FDA Approves Rasonque™ (daraxonrasib) Pancreatic Cancer Action Network FDA approves breakthrough drug daraxonrasib to treat pancreatic cancer BBC
- France Info (France)21:56
Développé par la start-up américaine Revolution Medicines, ce médicament est nommé Rasonque et pourra être pris sous la forme de comprimés .
- BBC News World22:02
Experts have hailed the drug, daraxonrasib, as a game changer for one of the world's deadliest cancers.
- Google News - Top Stories23:54
FDA approves pancreatic cancer drug that extends patients’ lives The Washington Post F.D.A. Approves the Drug Daraxonrasib That’s Poised to Transform Pancreatic Cancer The New York Times FDA approves once-daily pill for deadly cancer after patients' survival rates nearly double Fox News U.S. approves breakthrough pancreatic cancer drug, heralding a new era for an intractable disease Scientific American FDA Approves RASONQUE™ (daraxonrasib) Pancreatic Cancer Action Network
Thu, 27 August 2026
9 reports- Google News - Top Stories06:54
FDA approves landmark pancreatic cancer drug that's shown to improve survival NPR F.D.A. Approves the Drug Daraxonrasib That’s Poised to Transform Pancreatic Cancer The New York Times As RevMed preps for ‘historic’ pancreatic cancer launch, questions linger on the ground Fierce Pharma FDA Approves Drug for Pancreatic Cancer in Milestone for Treatment of Deadly Disease WSJ U.S. approves breakthrough pancreatic cancer drug, heralding a new era for an intractable disease Scientific American
- iheart.com08:56
The FDA has approved RASONQUE, a new pill that doubles survival rates for advanced pancreatic cancer patients. This once-daily treatment targets RAS mutations and significantly improves quality of life. It marks a major advancement in cancer treatment, offering hope to patients.
- iheart.com08:56
The FDA has approved RASONQUE, a new pill that doubles survival rates for advanced pancreatic cancer patients. This once-daily treatment targets RAS mutations and significantly improves quality of life. It marks a major advancement in cancer treatment, offering hope to patients.
- iheart.com08:56
The FDA has approved RASONQUE, a new pill that doubles survival rates for advanced pancreatic cancer patients. This once-daily treatment targets RAS mutations and significantly improves quality of life. It marks a major advancement in cancer treatment, offering hope to patients.
- iheart.com08:56
The FDA has approved RASONQUE, a new pill that doubles survival rates for advanced pancreatic cancer patients. This once-daily treatment targets RAS mutations and significantly improves quality of life. It marks a major advancement in cancer treatment, offering hope to patients.
- Libération (France)09:41
Le Rasonque, nom commercial du daraxonrasib, a montré des résultats très encourageants en doublant la durée de survie des malades de cette forme de cancer très agressive. Après le feu vert de l’agence américaine du médicament, annoncé le 26 août, celui de son homologue européenne pourrait suivre.
- ČT24 (Czechia)09:55
Experimentální lék proti rakovině slinivky břišní by měl změnit léčbu této rychle zabíjející nemoci. Ve středu ho schválila americká léková agentura FDA, evropské úřady už na schvalování pracují také.
- iDNES (Czechia)14:10
Americký Úřad pro kontrolu potravin a léčiv (FDA) schválil nový lék na rakovinu slinivky břišní. Má podobu tablety a oproti běžné chemoterapii dokáže téměř zdvojnásobit průměrnou dobu přežití pacientů s jedním z nejsmrtelnějších typů rakoviny. Vědci označili tento lék, který je známý pod obchodním názvem Rasonque nebo podle účinné látky daraxonrasib, za průlomový pokrok. Jeho vývoj byl jednou z nejsledovanějších událostí týkajících se experimentálních léčebných metod rakoviny.
- americanbazaaronline.com14:16
FDA approves daraxonrasib, the first targeted pill for advanced pancreatic cancer, offering patients longer survival and fewer side effects.
Fri, 28 August 2026
4 reports- Die Zeit (Germany)13:31
In den USA wurde ein neues Mittel gegen Bauchspeicheldrüsenkrebs zugelassen: Daraxonrasib. Wie es wirkt, wann es kommt – und was das für andere Tumorarten bedeutet
- Google News - Top Stories14:13
New pancreatic cancer drug carries a $39,800 monthly list price: What to know Yahoo Finance FDA Approves Drug for Pancreatic Cancer in Milestone for Treatment of Deadly Disease WSJ FDA approves breakthrough drug daraxonrasib to treat pancreatic cancer BBC New Drug Approved by F.D.A. for Pancreatic Cancer Could Be First of Many The New York Times Revolution pancreatic cancer drug should quickly become a blockbuster, analysts say BioPharma Dive
- yahoo.com20:54
Revolution Medicines, Inc. (NASDAQ:RVMD) touched an all-time high above $224 on August 27, 2026, following FDA approval of Rasonque (daraxonrasib) – the first broad RAS-targeted therapy cleared for metastatic pancreatic cancer. Creating a milestone, the approval came roughly five weeks after filing under the agency’s national priority voucher. The pivotal RASolute 302 trial nearly doubled […]
- PBS NewsHour22:40
There have been several promising developments lately in cancer research and treatment, including a new drug approved by the FDA this week for advanced pancreatic cancer. William Brangham reports.
Mon, 31 August 2026
2 reports- Google News - Top Stories09:03
A $480,000-a-Year Pill Reflects a New Normal for Cancer Drugs The New York Times Why Revolution Medicines, the Drugmaker Behind a Pancreatic Cancer Breakthrough, Stayed Independent WSJ Opinion | Trump’s cuts threaten access to a life-saving pancreatic cancer drug MS NOW As RevMed preps for ‘historic’ pancreatic cancer launch, questions linger on the ground Fierce Pharma U.S. approves breakthrough pancreatic cancer drug, heralding a new era for an intractable disease Scientific American
- Wirtualna Polska (Poland)17:42
Amerykańska Agencja Żywności i Leków (FDA) w trybie przyspieszonym dopuściła do obrotu lek Rasonque (daraksonrasib) dla części pacjentów z zaawansowanym rakiem trzustki. W badaniu klinicznym terapia w tabletkach wydłużyła medianę przeżycia do 13,2 miesiąca i zmniejszyła ryzyko zgonu o ok. 60 proc.
Wed, 2 September 2026
2 reports- Google News - Top Stories21:06
Daraxonrasib for Previously Treated RAS -Mutant Non–Small-Cell Lung Cancer The New England Journal of Medicine Breakthrough Pancreatic Cancer Drug Shows Promise In Lung Cancer Trial forbes.com A $480,000-a-Year Pill Reflects a New Normal for Cancer Drugs The New York Times FDA approves landmark pancreatic cancer drug that's shown to improve survival WUSA9 Pancreatic cancer drug may hold promise for lung cancer as well, early study suggests ABC News - Breaking News, Latest News and Videos
- Google News - Top Stories21:19
Landmark pancreatic cancer drug shows potential against lung cancer too Nature FDA approves landmark pancreatic cancer drug that's shown to improve survival WUSA9 Breakthrough Pancreatic Cancer Drug Shows Promise In Lung Cancer Trial Forbes A $480,000-a-Year Pill Reflects a New Normal for Cancer Drugs The New York Times RevMed’s newly approved Rasonque could ‘hold up’ in non-small cell lung cancer BioSpace
Tue, 8 September 2026
2 reports- Google News - Top Stories08:31
A breakthrough pancreatic cancer drug won approval. They still struggle to access it STAT Oncologists say newly approved pancreatic cancer drug is a breakthrough for treatment Healthcare Brew Pancreatic cancer drug may hold promise for lung cancer as well, early study suggests abcnews.com FDA approves landmark pancreatic cancer drug that's shown to improve survival WUSA9 David Gandara: Daraxonrasib Marks a Major Advance in Pancreatic Cancer Care Oncodaily
- rttnews.com15:18
Veru Inc. plans to advance oral sabizabulin into a Phase 2b trial for metastatic KRAS-driven pancreatic cancer that progresses despite daraxonrasib. Preclinical data showed potent activity in daraxonrasib-resistant pancreatic cancer cells, with an IC50 of 18.